" "
News

Dr. Reddy’s Laboratories announces the launch of Cefixime for Oral Suspension, USP in the U.S. Market

Dr Reddy

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Cefixime for Oral Suspension, USP 100 mg/5mL and 200 mg/5mL, a therapeutic equivalent generic version of Suprax® (cefixime) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

Dr Reddy

The Suprax® brand and generic had U.S. sales of approximately $50.5 million MAT for the most recent twelve months ending in June 2017 according to IMS Health*.

Dr. Reddy’s Cefixime for Oral Suspension, USP is available in strengths of 100 mg/5mL and 200 mg/5mL after reconstitution. The 100 mg/5 mL strength is available in 50 mL bottles. The 200 mg/5 mL strength is available in 75 mL and 50 mL bottles.

Suprax® is a registered trademark of Astellas Pharma Inc.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
" "
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

" "
To Top